FDA_Warning_Letters, Import_Alerts_&_EU_Non-Compliances_in_2019
X

Find Novel Oncology Drugs in Discovery in UNITED STATES

A collaboration with SCORR Marketing

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type

            Companies

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): T-cell bispecific antibodies

            Therapeutic Area: Oncology

            Highest Development Status: Discovery Product Type: Large molecule

            Partner/Sponsor/Collaborator: Astellas

            Deal Size: $1,600.0 million Upfront Cash: $80.0 million

            Deal Type: Collaboration March 23, 2020

            Details:

            Under this collaboration, the parties will utilize CytomX’s Probody® therapeutic technology platform, as well as its proprietary bispecific formats and CD3 modules.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): XTX201

            Therapeutic Area: Oncology

            Highest Development Status: Discovery Product Type: Large molecule

            Partner/Sponsor/Collaborator: Takeda Ventures

            Deal Size: $100.5 million Upfront Cash: Undisclosed

            Deal Type: Series B Financing March 02, 2020

            Details:

            Proceeds from the financing will be used to progress Xilio’s first two therapeutic candidates, XTX201 and XTX101 through Investigational New Drug enabling studies and into Phase 1 clinical trials.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): RP-182,Gemcitabine

            Therapeutic Area: Oncology

            Highest Development Status: Discovery Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable February 13, 2020

            Details:

            RP-182, administered in combination with gemcitabine, produced the best results ever shown in NCI’s KRAS-p16 pancreatic cancer model.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Undisclosed

            Therapeutic Area: Oncology

            Highest Development Status: Discovery Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable February 09, 2020

            Details:

            Data demonstrate potential to increase efficacy of TIL adoptive cell therapy in preclinical models.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Undisclosed

            Therapeutic Area: Oncology

            Highest Development Status: Discovery Product Type: Small molecule

            Partner/Sponsor/Collaborator: Pfizer

            Deal Size: $507.0 million Upfront Cash: $15.0 million

            Deal Type: Collaboration January 09, 2020

            Details:

            This license and collaboration agreement is to develop small-molecule inhibitors of eukaryotic initiation factor 4E, a key oncogenic driver located downstream from both the RAS and PI3K pathways.